Evidence method
Level · gp.fundamentals.debt_to_revenue
208.33% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ARDX · Jun 30, 2026
ARDELYX, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration
State dimensions
Filing0001437402-26-000044General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.01% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-5.29% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
23.77% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
114.98% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
95.24% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-10.28% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
21.59% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
12.67% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History32 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/9 normalizedLevel 3Dec 31, 20228/9 normalizedLevel 3Mar 31, 20238/9 normalizedLevel 3Jun 30, 20238/9 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/9 normalizedLevel 3Mar 31, 20249/9 normalizedLevel 3Jun 30, 20249/9 normalizedLevel 3Sep 30, 20249/9 normalizedLevel 3Dec 31, 20249/9 normalizedLevel 3Mar 31, 20259/9 normalizedLevel 3Jun 30, 20259/9 normalizedLevel 3Sep 30, 20259/9 normalizedLevel 3Dec 31, 20259/9 normalizedLevel 3Mar 31, 20269/9 normalizedLevel 3Jun 30, 20269/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 215.42%
- Current
- 208.33%
- Delta
- -7.09%
- Previous
- 0.07%
- Current
- 0.01%
- Delta
- -0.06%
- Previous
- -34.12%
- Current
- -5.29%
- Delta
- 28.83%
- Previous
- 27.47%
- Current
- 23.77%
- Delta
- -3.70%
- Previous
- 135.51%
- Current
- 114.98%
- Delta
- -20.53%
- Previous
- 94.91%
- Current
- 95.24%
- Delta
- 0.33%
- Previous
- -34.71%
- Current
- -10.28%
- Delta
- 24.43%
- Previous
- 21.37%
- Current
- 21.59%
- Delta
- 0.23%
- Previous
- 14.99%
- Current
- 12.67%
- Delta
- -2.32%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
- Similarity
- 90%
- Compared
- 9 dimensions
- Coverage
- 100%
- Similarity
- 85%
- Compared
- 9 dimensions
- Coverage
- 100%
- Similarity
- 82%
- Compared
- 7 dimensions
- Coverage
- 78%
- Similarity
- 75%
- Compared
- 8 dimensions
- Coverage
- 89%
- Similarity
- 74%
- Compared
- 9 dimensions
- Coverage
- 100%
Research Graph
Related governed research
Analogous To · ARDX state analogue 3 →Analogous To · ARDX state analogue 2 →Compared To · Pharmaceutical Preparations peers →Analogous To · ARDX state analogue 4 →Analogous To · ARDX state analogue 5 →Analogous To · ARDX state analogue 1 →Derived From · ARDX Company Quality Vector →Has State · ARDELYX, INC. →Transitioned To · ARDX MARGIN_INCREASED →Transitioned To · ARDX PROFITABILITY_INCREASED →Transitioned To · ARDX R_AND_D_INTENSITY_INCREASED →Transitioned To · ARDX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.